December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

167.09 +0.48 (+0.29%)
Streaming Delayed Price Updated: 10:05 AM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
3 Magnificent Stocks Retirees Can Buy and Hold Forever
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.
The market previously supported a higher multiple for these undervalued stocks, making them attractive contrarian targets. 
Via InvestorPlace
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice. 
Via InvestorPlace
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Income-seeking investors can find plenty of opportunities in any market environment. 
Via The Motley Fool
4 Cheap Stocks to Buy in July
All four of these stocks are trading at very intriguing valuations. 
Via The Motley Fool
Exploring NYSE:JNJ's dividend characteristics.
Analyzing JOHNSON & JOHNSON (NYSE:JNJ)'s Dividend Potential. 
Via Chartmill
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
Via Benzinga
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
A look at 10 blue-chip dividend growth stocks with yields above 3%, the opportunity for those yields to continue growing in the future, and where we can be very certain that the dividend is safe. 
Via Talk Markets
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue
From Beasley Allen
Via Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Exposures Product Safety
2 Incredible Dividend Growth Stocks to Buy Right Now
These two dividend growth stocks can level up your portfolio. 
Via The Motley Fool
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson's business is growing at a decent rate, but there's still a fair bit of risk surrounding the company. 
Via The Motley Fool
The 3 Smartest Dow Stocks to Buy With $1000 Right Now
Explore why these three well-known Dow stocks to buy are well worth your next $1,000 investment to grow your portfolio. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
J&J is the textbook blue chip stock -- but it's not for everyone. 
Via The Motley Fool
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
The Top 3 Sectors Poised For Growth This Summer
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides. 
Via MarketBeat
Topics ETFs
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
The pharmaceutical industry giants offer reliable profit growth and above-average dividend yields. 
Via The Motley Fool
2 Top Stocks to Buy Now for Years of Passive Income
These tried-and-true businesses could be wise additions to your portfolio. 
Via The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products
Johnson & Johnson faces a new class action lawsuit seeking damages and medical monitoring for cancer risk from talc products. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
From Beasley Allen
Via Business Wire
Johnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease
Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met all primary and secondary endpoints. 
Via Benzinga
3 Healthcare Stocks to Buy Now: June 2024
Invest in healthcare stocks to buy now, benefiting from robust product pipelines and tech advancements at this time. 
Via InvestorPlace
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Discover these blue-chip stocks to buy in the biotechnology, banking, pharmaceuticals, tobacco, restaurants, and entertainment industries. 
Via InvestorPlace
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
These healthcare players offer you dividends and a strong earnings picture. 
Via The Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
A modest amount of money can go a long when when it's put to work in game-changing businesses with well-defined catalysts. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.